Can You Take Ozempic with High Blood Pressure? Your Guide to Safe Treatment

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

High blood pressure is not a contraindication to Ozempic. The only contraindications in its labeling are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and serious hypersensitivity to semaglutide or its excipients. Hypertension appears nowhere on that list. What the evidence does show is that semaglutide tends to lower systolic blood pressure modestly while raising heart rate slightly, and that people with hypertension are frequently on medications whose absorption or effect warrants attention when gastric emptying slows. Whether it is appropriate for you is a clinical judgement, not a general one.

What the Contraindications Section Says

Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2, and in patients with a serious hypersensitivity reaction to semaglutide or any of the excipients. That is the complete list.

Blood pressure is not among the labeled warnings and precautions either. Those cover acute pancreatitis, diabetic retinopathy complications, never sharing a pen between patients, hypoglycemia with concomitant insulin secretagogues or insulin, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation.

The absence of a hypertension warning is not the same as a clearance for any individual. It means the label does not treat hypertension as a barrier, and the assessment moves to your prescriber.

What the Trials Measured

Study 1 in the Wegovy label — the large cardiovascular outcomes trial in 8,801 and 8,803 participants — reported mean changes at week 104 including a systolic blood pressure reduction of 3.8 mmHg with semaglutide from a baseline of 131 mmHg, versus 0.5 mmHg with placebo, a difference of 3.3 mmHg.

The same table reported a mean heart rate increase of 3.8 beats per minute with semaglutide versus 0.7 with placebo, a difference of 3.1 beats per minute. A small rise in heart rate is a recognised class effect of GLP-1 receptor agonists.

That trial also reported a primary composite cardiovascular endpoint of 6.5% with semaglutide versus 8% with placebo, a hazard ratio of 0.80 (95% CI 0.72 to 0.90). This is the evidence underlying Wegovy’s cardiovascular indication — noting that Ozempic’s own cardiovascular indication applies to adults with type 2 diabetes and established cardiovascular disease.

Why Blood Pressure Often Falls

Weight reduction itself lowers blood pressure, and the reductions observed in these trials track closely with the weight changes. In Study 1 the mean body weight change was −9.4 kg with semaglutide versus −0.93 kg with placebo at week 104.

Reduced sodium intake follows almost automatically from reduced total intake, which contributes independently. Improvements in insulin sensitivity and in obstructive sleep apnea severity may contribute as well.

The practical consequence is that a person on antihypertensive therapy who loses substantial weight may become over-treated for their new physiology. Symptoms such as light-headedness on standing are worth reporting rather than tolerating, because they can signal that the antihypertensive regimen needs review — a review your prescriber conducts.

The Interaction That Matters Most Is Volume

The Ozempic label carries a warning for acute kidney injury due to volume depletion, and directs that renal function be monitored in patients reporting adverse reactions that could lead to it. Nausea, vomiting and diarrhea are the relevant reactions.

That risk compounds with diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which are among the most commonly prescribed antihypertensive drugs. The combination of gastrointestinal fluid losses and a regimen that already limits renal compensation is the specific scenario to be alert to.

Persistent vomiting or diarrhea on this class is therefore not a nuisance to push through when you are on those medications. It is a reason to contact your prescriber.

Oral Medications and Gastric Emptying

Ozempic section 7.2 states that the drug delays gastric emptying and has the potential to affect absorption of concomitantly administered oral medications, that clinical pharmacology trials showed no clinically relevant effect on absorption, and that caution should nonetheless be exercised.

Wegovy section 7.2 goes further, directing prescribers to monitor the effects of concomitant oral medications and to consider increased clinical or laboratory monitoring for drugs with a narrow therapeutic index or that require clinical monitoring.

Most antihypertensive drugs do not have a narrow therapeutic index, but many people with hypertension take other medications that do. A complete medication list is the single most useful thing you can bring to the appointment.

What Monitoring Looks Like in Practice

Reasonable follow-up includes home blood pressure readings recorded with dates, periodic renal function and electrolyte checks, attention to symptoms of volume depletion, and a review of the antihypertensive regimen as weight changes.

Report new palpitations or a persistently elevated resting pulse. The heart rate increase seen in trials was small on average, but averages do not describe individuals, and this is a reasonable thing to raise.

Finally, be precise about which product you are discussing. Ozempic is approved for type 2 diabetes indications; Wegovy carries the weight-management and cardiovascular risk reduction indications in adults with overweight or obesity. Compounded semaglutide is neither, and has no FDA-reviewed labeling of its own.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is high blood pressure a contraindication to Ozempic?

No. The Ozempic label lists only two contraindications: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and serious hypersensitivity to semaglutide or its excipients. Hypertension is not among them and does not appear in the warnings and precautions section either. Whether the medication suits you individually remains a clinical judgement.

Does semaglutide raise or lower blood pressure?

In the large cardiovascular outcomes trial reported in the Wegovy label, systolic blood pressure fell by a mean of 3.8 mmHg with semaglutide versus 0.5 mmHg with placebo at week 104, a difference of 3.3 mmHg from a baseline of 131 mmHg. Heart rate rose by a mean of 3.8 beats per minute versus 0.7 with placebo, a recognised class effect.

Will I need my blood pressure medication adjusted?

Possibly, and that is a decision for your prescriber. Substantial weight loss lowers blood pressure, so a regimen calibrated to your previous physiology may become excessive. Symptoms such as light-headedness on standing are worth reporting promptly rather than tolerating. Do not change or stop an antihypertensive medication on your own initiative.

What is the main risk when combining these medications?

Volume depletion. The Ozempic label warns about acute kidney injury due to volume depletion and directs monitoring of renal function in patients reporting reactions that could lead to it. Nausea, vomiting and diarrhea combined with diuretics, ACE inhibitors or angiotensin receptor blockers is the specific scenario of concern, and persistent symptoms warrant contacting your prescriber.

Does Ozempic have a cardiovascular benefit?

It carries an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Wegovy carries a separate cardiovascular indication for adults with established cardiovascular disease and either obesity or overweight, supported by a trial reporting a primary composite endpoint of 6.5% versus 8% with placebo, hazard ratio 0.80.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.